Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in type 2 diabetes

Endocrine Journal

Volumn 56, Issue 5, 2009, Pages 691-698

  Tsuchiya, Kyoichiro ^a   Akaza, Itaru ^a   Yoshimoto, Takanobu ^a   Hirata, Yukio ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Adiponectin; Flow mediated vasodilation; Thiazolidinediones

Indexed keywords

ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; ECHOGRAPHY; ENDOTHELIUM; FEMALE; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; VASODILATATION;

ADIPONECTIN; AGED; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; VASODILATION;

EID: 69249215302     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K08E-308     Document Type: Article

References (31)

1. Deanfield JE, Halcox JP, Rabelink TJ (2007) Endothelial function and dysfunction: testing and clinical relevance. Circulation 115: 1285-1295. (Pubitemid 46594773)
2. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683-689. (Pubitemid 32893993)
3. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334: 952-957. (Pubitemid 26114161)
4. Deedwania PC (2004) Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? Circulation 109: 2-4.
5. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340: 1111-1115.
6. rd (1995) Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 91: 1732-1738.
7. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield Je (1994) Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 24: 471-476. (Pubitemid 24246550)
8. John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, Schmieder RE (1998) Increased bioavailability of nitric oxide after lipidlowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 98: 211-216. (Pubitemid 28337611)
9. Rask-Madsen C, King GL (2007) Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 3: 46-56. (Pubitemid 46006612)
10. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86: 1930-1935. (Pubitemid 32472900)
11. Bisoendial RJ, Hovingh GK, Levels JH, Lerch PG, Andresen I, Hayden MR, Kastelein JJ, Stroes ES (2003) Restoration of endothelial function by increasing highdensity lipoprotein in subjects with isolated low highdensity lipoprotein. Circulation 107: 2944-2948. (Pubitemid 36736637)
12. Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, Jackson SK, Lewis MJ, Frenneaux MP, Rees A (2000) Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 101: 1773-1779. (Pubitemid 30213097)
13. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa y (2001) PPargamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50: 2094-2099.
14. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ (2005) A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28: 1547-1554. (Pubitemid 40923063)
15. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P (2004) In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27: 484-490. (Pubitemid 38174076)
16. Tsuchiya K, Nakayama C, Iwashima F, Sakai H, Izumiyama H, Doi M, Hirata Y (2007) Advanced Endothelial Dysfunction in Diabetic Patients with Multiple Risk Factors; Importance of Insulin Resistance. J Atheroscler Thromb 14: 303-309.
17. Yu HI, Sheu WH, Lai CJ, Lee WJ, Chen YT (2001) Endothelial dysfunction in type 2 diabetes mellitus subjects with peripheral artery disease. Int J Cardiol 78: 19-25. (Pubitemid 32232133)
18. Tan KC, Xu A, Chow WS, Lam MC, Ai VH, Tam SC, Lam KS (2004) Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 89: 765-769. (Pubitemid 38269891)
19. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599. (Pubitemid 30353893)
20. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ (2003) Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278: 45021-45026. (Pubitemid 37377262)
21. Bahia L, Aguiar LG, Villela N, Bottino D, Godoymatos AF, Geloneze B, Tambascia M, Bouskela E (2007) Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome. Atherosclerosis 195: 138-146. (Pubitemid 47566382)
22. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA (2004) Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 89: 4312-4319. (Pubitemid 39244431)
23. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM (2002) Synthetic peroxisome proliferator-activated receptor- gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25: 376-380. (Pubitemid 41079639)
24. Mineo C, Yuhanna IS, Quon MJ, Shaul PW (2003) High density lipoprotein-induced endothelial nitricoxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 278: 9142-9149. (Pubitemid 36800395)
25. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Luscher TF, Noll G (2002) High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105: 1399-1402. (Pubitemid 34263266)
26. Duan SZ, Usher MG, Mortensen RM (2008) Peroxisome proliferator-activated receptor-gammamediated effects in the vasculature. Circ Res 102: 283-294.
27. Pasceri V, Wu HD, Willerson JT, Yeh ET (2000) Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptorgamma activators. Circulation 101: 235-238. (Pubitemid 30054148)
28. Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, Demer LL (1999) Peroxisome proliferator- activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 19: 2094-2104. (Pubitemid 29422240)
29. Verrier E, Wang L, Wadham C, Albanese N, Hahn C, Gamble JR, Chatterjee VK, Vadas MA, Xia P (2004) PPargamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase c signaling pathway: role of diacylglycerol kinase. Circ Res 94: 1515-1522. (Pubitemid 38780325)
30. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM (2005) Peroxisome proliferator-activated receptor gam ma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 25: 1810-1816.
31. Buras J, Reenstra WR, Orlow D, Horton Es, Veves A (2005) Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes. Obes Res 13: 1167-1174.